Log in

NASDAQ:MEDPMedpace Stock Price, Forecast & News

$68.08
-3.84 (-5.34 %)
(As of 04/6/2020 06:43 AM ET)
Add
Compare
Today's Range
$66.78
Now: $68.08
$72.75
50-Day Range
$61.71
MA: $85.42
$101.95
52-Week Range
$52.84
Now: $68.08
$109.09
Volume357,399 shs
Average Volume537,512 shs
Market Capitalization$2.48 billion
P/E Ratio25.69
Dividend YieldN/A
Beta1.33
Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its drug development services include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Read More
Medpace logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEDP
CUSIPN/A
Phone513-579-9911

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$860.97 million
Cash Flow$3.79 per share
Book Value$20.16 per share

Profitability

Net Income$100.44 million

Miscellaneous

Employees3,500
Market Cap$2.48 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive MEDP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.


Medpace (NASDAQ:MEDP) Frequently Asked Questions

How has Medpace's stock been impacted by COVID-19 (Coronavirus)?

Medpace's stock was trading at $83.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MEDP stock has decreased by 18.6% and is now trading at $68.08. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Medpace?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medpace.

When is Medpace's next earnings date?

Medpace is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Medpace.

How were Medpace's earnings last quarter?

Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings data on Monday, February, 24th. The company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.10. The business had revenue of $229.89 million for the quarter, compared to analysts' expectations of $221.73 million. Medpace had a net margin of 11.67% and a return on equity of 16.80%. Medpace's revenue was up 19.7% on a year-over-year basis. During the same period last year, the business earned $0.76 EPS. View Medpace's earnings history.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY 2020 After-Hours earnings guidance on Monday, February, 24th. The company provided earnings per share guidance of 3.24-3.34 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.28. The company issued revenue guidance of $975M - 1.005 billion, compared to the consensus revenue estimate of $977.76 million.

What price target have analysts set for MEDP?

5 analysts have issued 12 month price targets for Medpace's shares. Their forecasts range from $46.00 to $99.00. On average, they expect Medpace's stock price to reach $76.20 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price. View analysts' price targets for Medpace.

Has Medpace been receiving favorable news coverage?

Media headlines about MEDP stock have trended very negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medpace earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutMedpace.

Who are some of Medpace's key competitors?

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Alibaba Group (BABA), Adobe (ADBE), Baidu (BIDU), Paycom Software (PAYC), Cyberark Software (CYBR), Paypal (PYPL), Veeva Systems (VEEV) and Fortinet (FTNT).

Who are Medpace's key executives?

Medpace's management team includes the following people:
  • Dr. August James Troendle, Chairman, Pres & CEO (Age 63)
  • Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 45)
  • Ms. Susan E. Burwig, Exec. VP of Operations (Age 56)
  • Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Todd Meyers, VP of Bus. Devel. & Marketing

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is Medpace's stock symbol?

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Who are Medpace's major shareholders?

Medpace's stock is owned by a variety of institutional and retail investors. Top institutional investors include McGuire Investment Group LLC (0.14%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View institutional ownership trends for Medpace.

Which institutional investors are buying Medpace stock?

MEDP stock was bought by a variety of institutional investors in the last quarter, including McGuire Investment Group LLC. View insider buying and selling activity for Medpace.

How do I buy shares of Medpace?

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medpace's stock price today?

One share of MEDP stock can currently be purchased for approximately $68.08.

How big of a company is Medpace?

Medpace has a market capitalization of $2.48 billion and generates $860.97 million in revenue each year. The company earns $100.44 million in net income (profit) each year or $3.02 on an earnings per share basis. Medpace employs 3,500 workers across the globe. View additional information about Medpace.

What is Medpace's official website?

The official website for Medpace is http://www.medpace.com/.

How can I contact Medpace?

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]

This page was last updated on 4/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel